Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.

@article{Gordon2004Yttrium9I,
  title={Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.},
  author={Leo I Gordon and Thomas E Witzig and Arturo Molina and Myron S. Czuczman and Christos Emmanouilides and Robin Joyce and Katie Vo and Charles P. Theuer and Brad L Pohlman and Nancy L. Bartlett and Greg Wiseman and Mohamed Darif and Christine A. White},
  journal={Clinical lymphoma},
  year={2004},
  volume={5 2},
  pages={98-101}
}
We report updated time-to-event variables of a phase III randomized study comparing yttrium 90-labeled ibritumomab with rituximab standard therapy in 143 rituximab-naive patients with relapsed or refractory low-grade, follicular, or transformed CD20+ non-Hodgkin's lymphoma (NHL). Most patients (79%) had follicular lymphoma. Patients were randomized to receive a single intravenous (I.V.) dose of 90Y ibritumomab tiuxetan 0.4 mCi/kg (n = 73) or rituximab 375 mg/m2 I.V. weekly for 4 doses (n = 70… CONTINUE READING
37 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Similar Papers

Loading similar papers…